Yanhong Shang

No. 648, Dongfeng East Road
Baoding, 071000, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Chinese expert consensus on precision diagnosis and treatment of refractory tumors.

Chinese expert consensus on precision diagnosis and treatment of refractory tumors.

Journal: Critical reviews in oncology/hematology

Published: October 29, 2025

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.

Journal: Cancer biology & medicine

Published: April 09, 2025

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.

Journal: Lancet (London, England)

Published: September 14, 2024

Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial.

Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial.

Journal: Nature medicine

Published: June 11, 2024

Cullin7 induces docetaxel resistance by regulating the protein level of the antiapoptotic protein Survivin in lung adenocarcinoma cells.

Cullin7 induces docetaxel resistance by regulating the protein level of the antiapoptotic protein Survivin in lung adenocarcinoma cells.

Journal: Journal of thoracic disease

Published: July 17, 2023

Plasma proteome profiling reveals dynamic of cholesterol marker after dual blocker therapy.

Plasma proteome profiling reveals dynamic of cholesterol marker after dual blocker therapy.

Journal: Nature communications

Published: June 28, 2023

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study.

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study.

Journal: Molecular cancer

Published: April 18, 2023

Radionecrosis mimicking pseudo‑progression in a patient with lung cancer and brain metastasis following the combination of anti‑PD‑1 therapy and stereotactic radiosurgery: A case report.

Radionecrosis mimicking pseudo‑progression in a patient with lung cancer and brain metastasis following the combination of anti‑PD‑1 therapy and stereotactic radiosurgery: A case report.

Journal: Oncology letters

Published: April 05, 2023

Telehealth With Comprehensive Live-Fed Real-World Data as a Patient Care Platform for Lung Cancer: Implementation and Evaluation Study.

Telehealth With Comprehensive Live-Fed Real-World Data as a Patient Care Platform for Lung Cancer: Implementation and Evaluation Study.

Journal: JMIR cancer

Published: December 28, 2022

Investigation of the prevalence and clinical implications of ERBB2 exon 16 skipping mutations in Chinese pan-cancer patients.

Investigation of the prevalence and clinical implications of ERBB2 exon 16 skipping mutations in Chinese pan-cancer patients.

Journal: Frontiers in oncology

Published: October 08, 2022

MMP11 is associated with the immune response and immune microenvironment in EGFR-mutant lung adenocarcinoma.

MMP11 is associated with the immune response and immune microenvironment in EGFR-mutant lung adenocarcinoma.

Journal: Frontiers in oncology

Published: September 27, 2022

The Interaction of the IFNγ/JAK/STAT1 and JAK/STAT3 Signalling Pathways in EGFR-Mutated Lung Adenocarcinoma Cells.

The Interaction of the IFNγ/JAK/STAT1 and JAK/STAT3 Signalling Pathways in EGFR-Mutated Lung Adenocarcinoma Cells.

Journal: Journal of oncology

Published: June 10, 2022

Showing 1-12 of 25

Last Updated: 09/26/2026